Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.
Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, Jeffrey D, Turaj AH, Rolfvondenbaumen K, Galloway C, Wynn T, Coleman AR, Ward B, Long K, Coleman H, Mundy C, Bates AT, Ayres D, Lown R, Falconer J, Brake O, Batchelor J, Willimott V, Bowzyk Al-Naeeb A, Robinson L, O'Callaghan A, Collins GP, Menne T, Faust SN, Fox CP, Ahearne M, Johnson PWM, Davies AJ, Goldblatt D. Lim SH, et al. Among authors: collins gp. Nat Cancer. 2022 May;3(5):552-564. doi: 10.1038/s43018-022-00364-3. Epub 2022 Mar 24. Nat Cancer. 2022. PMID: 35332334 Free PMC article.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM. Davies A, et al. Among authors: collins gp. Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948276 Free PMC article. Clinical Trial.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31222719 Free article.
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Booth S, Plaschkes H, Kirkwood AA, Gibb A, Horgan P, Higham C, Oladipo JM, Browning J, Khan U, Tseu B, Chen L, Willan J, Wolf J, Gunawan A, Fields P, Ebsworth T, Lown R, Gordon-Walker D, Shah N, Linton KM, Collins GP, Kothari J, Hildyard C, Eyre TA. Booth S, et al. Among authors: collins gp. Blood Adv. 2020 Sep 22;4(18):4337-4346. doi: 10.1182/bloodadvances.2020002553. Blood Adv. 2020. PMID: 32915975 Free PMC article.
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J. Gibb A, et al. Among authors: collins gp. Br J Haematol. 2021 Apr;193(1):63-71. doi: 10.1111/bjh.17073. Epub 2020 Sep 14. Br J Haematol. 2021. PMID: 32926420 Free article. Clinical Trial.
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
Davies A, Barrans S, Burton C, Mercer K, Caddy J, Chinnery F, Day L, Fernando D, Ardeshna K, Collins G, Radford J, Rule S, McMillan A, Johnson P, Griffiths G. Davies A, et al. F1000Res. 2020 Aug 7;9:941. doi: 10.12688/f1000research.22318.1. eCollection 2020. F1000Res. 2020. PMID: 33093947 Free PMC article.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: collins gp. Blood Adv. 2021 Apr 27;5(8):2229-2236. doi: 10.1182/bloodadvances.2021004286. Blood Adv. 2021. PMID: 33890978 Free PMC article.
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP. Martinez-Calle N, et al. Among authors: collins gp. Adv Ther. 2021 Jul;38(7):3789-3802. doi: 10.1007/s12325-021-01764-0. Epub 2021 May 26. Adv Ther. 2021. PMID: 34037958 Free PMC article.
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Hamadani M, et al. Among authors: collins gp. Lancet Haematol. 2021 Jun;8(6):e433-e445. doi: 10.1016/S2352-3026(21)00103-4. Lancet Haematol. 2021. PMID: 34048682 Free PMC article. Clinical Trial.
184 results